Description

MTIC-d3 is deuterium labeled MTIC. MTIC is the active metabolite of Temozolomide (TMZ). MITC has lower bioavailability in the brain compared with TMZ, because the agent’s permeability through biological barriers and tumor cell membranes affects bioavailability. MITC exhibits low affinity to biological membrane[1].–Applications-Cancer-programmed cell death-Formula-C5H5D3N6O-Citation–References-[1]Ramalho MJ, et al. Biophysical interaction of temozolomide and its active metabolite with biomembrane models: The relevance of drug-membrane interaction for Glioblastoma Multiforme therapy. Eur J Pharm Biopharm. 2019;136:156-163. |[2]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.-CASNumber-1185242-69-6-MolecularWeight-171.18-Compound Purity–SMILES-NC(C1=C(N=CN1)/N=N/NC([2H])([2H])[2H])=O-Research_Area-Cancer; Neurological Disease-Solubility-10 mM in DMSO-Target-Drug Metabolite;Isotope-Labeled Compounds-Isoform–Pathway-Metabolic Enzyme/Protease;Others-MCE Product type-Isotope-Labeled Compounds